Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 31 August 2017 Strong performance data of proprietary MSI Biomarkers for the Idylla™ MSI Test to be published at ESMO Non-regulated information 31 August 2017 Biocartis Announces 2017 Half-Year Results on 7 September 2017 Regulated information 9 August 2017 Invitation to the extraordinary shareholders' meeting Regulated information 12 July 2017 Biocartis’ Idylla™ Instrument and Idylla™ Console exempt from US FDA 510(k) notification requirements Non-regulated information 10 July 2017 Biocartis and A*STAR’s ETPL initiate development of breast cancer assay to guide therapy selection Non-regulated information 13 June 2017 Biocartis launches CE-marked IVD test for lung cancer Idylla™ EGFR Mutation Test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations according to international guidelines Non-regulated information 13 June 2017 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 7 June 2017 MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform Non-regulated information 2 June 2017 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 23 May 2017 Biocartis launches CE-marked IVD NRAS test for colorectal cancer Non-regulated information Pagination First page « First Previous page ‹‹ … Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Page 28 Page 29 … Next page ›› Last page Last »